Status: Recruiting
SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas
A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.
Participants needed: 18
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: The Affiliated Hospital of Qingdao UniversityUpdated: Aug 9, 2024Locations: 1
Eligibility criteria
Greater than or equal to 18 years of age [+3]
Active or uncontrollable infections or other active major medical illnesses of t... [+3]